American Society of Interventional Pain Physicians | March 6, 2019
July 13 - July 14 | Memphis, TN
The American Board of Interventional Pain Physicians ( ABIPP ) has developed certification programs that recognize accepted levels of knowledge and expertise in the interventional pain management
profession, with the goal of improved patient care. Hundreds of qualified physicians have made the commitment to become ABIPP certified.

Register before March 30, 2019. Fee only $1,000.

April 1 to May 30, 2019, fee is $2,000

May 1 to May 30, fee is total of $3,000

No registrations after May 30.

ABIPP now offers the only competency certification program for regenerative medicine.
For complete information about the examination requirements and to obtain an application packet, visit or call 270-554-9412 x4217 or by email at

July 13
July 13-14
July 14
ABIPP Competency Exam

July 13
Combined CSM/CCPM Exam for ABIPP Path
July 13
Competency Exam in Controlled Substance Managemen

July 13
Competency Exam in Coding, Compliance, and
Practice Management

July 13-14
Regenerative Medicine Competency Exam
July 13-14
Endoscopic Lumbar Decompression Competency Exam

939 Ridge Lake Blvd. | Memphis, TN 38120
The cut-off date for our room block with discounted rates is on June 10, 2019 or until sold out, whichever occurs first.
ASIPP Liability Insurance Program - with average premium reductions of 35%  

The ASIPP malpractice insurance program is up and running. Practices who have signed up are realizing tremendous savings - some as high as 60K per year. The program is specifically tailored to interventional pain management and works with multiple top rated carriers to secure the best rate and coverage.
ABIPP practices will be eligible for additional discounts off the ASIPP rate. The program along with the insurance carrier will be offering additional education and risk management programs specific to interventional pain management.
To proceed with this further and obtain the best rates possible please reach out to the insurance program broker & administrator.
Tom Wierzbowski
Willow Risk Advisors
 Ph –  267-448-5091 (Direct Line)
 Cell –  267-884-2729
Regenerative Medicine and Antithrombotic Guidelines Now Available

Responsible, Safe, and Effective Use of Biologics in the Management of Low Back Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines

Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients Undergoing Interventional Techniques: American Society of Interventional Pain Physicians (ASIPP) Guidelines

Exclusive: OxyContin maker Purdue Pharma exploring bankruptcy – sources

(Reuters) - OxyContin maker Purdue Pharma LP is exploring filing for bankruptcy to address potentially significant liabilities from roughly 2,000 lawsuits alleging the drugmaker contributed to the deadly opioid crisis sweeping the United States, people familiar with the matter said on Monday.
The potential move shows how Purdue and its wealthy owners, the Sackler family, are under pressure to respond to mounting litigation accusing the company of misleading doctors and patients about risks associated with prolonged use of its prescription opioids.

Nurses, Social Workers Demand Action on Workplace Violence

WASHINGTON -- House members discussed legislation aimed at protecting healthcare workers from violent patients during a hearing on Wednesday.
The purpose of Wednesday's hearing by the House Education and Labor Committee's Workforce Protections subcommittee was to examine the Workplace Violence Prevention for Health Care and Social Service Workers Act , recently re-introduced by Rep. Joe Courtney (D-Conn.)
Witnesses told of threats and injuries on the job. Some said the incidents ended their careers and shattered their health.

Big Pharma Targeted at Senate Hearing on Opioid Crisis
Sen. Durbin questions need to make 14 billion opioid doses per year

WASHINGTON -- Sen. Dick Durbin (D-Ill.) took aim at Big Pharma during a Senate hearing Thursday on the opioid crisis.
"A few years ago there was a committee hearing, and they dislcosed that the pharmaceutical industry asked for permission to produce 14 billion opioid doses a year ... so that every adult in America could then fill a prescription for 3 weeks," he said at the hearing held by the Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies. "They came up with 14 billion because they thought they could make money selling [that amount], and it was approved by the Drug Enforcement Administration. Think of that -- at a time when we're facing the worst drug epidemic in our history, a government agency is giving this industry permission to make 14 billion tablets!"

Interventional Pain Management Reports is an Open Access online journal, a peer-reviews journal dedicated to the publication of case reports, brief commentaries and reviews and letters to the editor. It is a peer-reviewed journal written by and directed to an audience of interventional pain physicians, clinicians and basic scientists with an interest in interventional pain management and pain medicine. 

Interventional Pain Management Reports is an official publication of the American Society of Interventional Pain Physicians (ASIPP) and is a sister publication of Pain Physician . Interventional Pain Management Reports Interventional Pain Management Reports is an open access journal, available online with free full manuscripts.  

The benefits of publishing in an open access journal that has a corresponding
print edition journal are:  
  • Your article will have the potential to obtain more citations.
  • Your article will be peer-reviewed and published faster than other journals.
  • Your article can be read by a potentially much larger audience compared with traditional subscription-only journals.  
  • Open Access journals are FREE to view, download and to print.

So submit today your:
  • Case Reports
  • Technical Reports
  • Editorials
  • Short Perspectives

Educational Program May Improve Opioid Prescribing Practices

A one-time education program regarding safe, responsible opioid prescribing for clinicians prescribing these medications for the management of acute pain may improve their knowledge and confidence effectively and may increase guideline adherence, according to a study published in Pain Medicine.
All credentialed clinicians who prescribe opioids at the University of Washington (n=167) were requested to complete an educational program on safe and responsible opioid prescribing. Six months after completing the program, clinicians were asked to complete an online survey regarding their perception of improvements in knowledge and perceived competence in managing opioids for acute pain as well as on the impact of the use of 3 guidelines in clinical practice.

High Frequency TENS Beneficial in Chronic Low Back Pain

Daily use of a high-frequency transcutaneous electrical nerve stimulation (hfTENS) device may reduce pain and improve function in patients with chronic low back pain (CLBP), according to a study published in Pain Practice.
Cutaneous stimulation was found to be associated with analgesic benefits in individuals with neuropathic or musculoskeletal pain, but the underlying mechanisms are not well understood. Investigators sought to evaluate the safety and efficacy of an hfTENS device for the treatment of mechanical CLBP.

New Drug Combination May Be An Effective Prophylactic for Opioid-Induced Nausea

CL-108, a new combination of a low-dose antiemetic with hydrocodone and acetaminophen, may be a safe and effective prophylactic medication for the treatment of opioid-induced nausea and vomiting (OINV) in individuals treated for moderate to severe acute pain, according to a study published in Pain Medicine.
CL-108, which consists of rapid-release 12.5 mg promethazine combined with 7.5 mg hydrocodone (HC) and 325 mg acetaminophen (APAP), was developed to reduce moderate to severe acute pain without opioid treatment-associated nausea. A total of 466 patients with moderate to severe pain associated with surgical removal of ≥2 affected third molar teeth (with ≥1 mandibular affected) were enrolled in this multicenter study. Pain was evaluated using a categorical pain intensity scale (PI-CAT). Participants were randomly assigned to receive CL-108 (n=211), HC/APAP (n=205), or placebo (n=50). Medications were taken on an as-needed basis every 4 to 6 hours. Participants were asked to self-assess their pain using the PI-CAT at regular intervals during a 24-hour period. Prospective assessments of nausea, vomiting, and other opioid-related adverse events were also performed. Co-primary end points included incidence of OINV and changes in pain intensity during the assessment period.

2019 MIPS Reporting? Start Now.
MIPS-eligible clinicians must report a full year of data. Don’t fall behind – keep up with NIPM-QCDR.
MIPS 2019 has brought larger payment adjustments and greater reporting requirements, including a 365-day performance period for the Quality and Cost categories. The sooner you start your MIPS reporting for 2019, the better.
Sign up today to use ASIPP’s NIPM-QCDR for MIPS.
This powerful tool makes MIPS reporting easy through the use of our new patient-reported outcomes measures for 2019, which ease the burden on providers and reduces costly EMR integration.

Get started today at

Evidence based medicine: a movement in crisis?

Trisha Greenhalgh and colleagues argue that, although evidence based medicine has had many benefits, it has also had some negative unintended consequences.They offer a preliminary agenda for the movement’s renaissance, refocusing on providing useable evidence that can be combined with context and professional expertise so that individual patients get optimal treatment

It is more than 20 years since the evidence based medicine working group announced a “new paradigm” for teaching and practising clinical medicine.1 Tradition, anecdote, and theoretical reasoning from basic sciences would be replaced by evidence from high quality randomised controlled trials and observational studies, in combination with clinical expertise and the needs and wishes of patients.


Pain Physician
January/February 2019 Issue Features

Sjors H. Wagemakers, MD, Joanne M. van der Velden, MD, PhD, A. Sophie Gerlich, MD, Alinde W. Hindriks-Keegstra, MD, Jacqueline F.M. van Dijk, PhD, and Joost J.C. Verhoeff, MD, PhD.
Cui Zhiyong, MD, Tian Yun, MD, Feng Hui, MD, Yang Zhongwei, MD, and Liu Zhaorui, MD.

Zung Vu Tran, PhD, Anna Ivashchenko, MPH, and Logan Brooks, BA.
Peng-Fei Wu, BD, Ya-Wei Li, MD, Bing Wang, MD, Bin Jiang, BD, Zhi-Ming Tu, BD, and Guo-Hua Lv, MD.

Parisa Nejati, MD, Afsaneh Safarcherati, MD, and Farshid Karimi, MD.

State Society News 

July 12-14, 2019
GSIPP 2019 - 15th Annual Meeting & Pain Summit
The Cloister Hotel at Sea Island
Sea Island, GA
For more information, contact Karrie Kirwan at or Tara Morrison at or 770-613-0932.

July 26-28, 2019
PAIN 2019
West Virginia Society of Pain Physicians
Loews Miami Beach, FL

Send in your state society meeting news to Holly Long,
ASIPP | Pain Physician Journal | Phone | Fax | Email